Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $54.00 up 5.43% from its previous closing price of $51.22. In other words, the price has increased by $5.43 from its previous closing price. On the day, 1.71 million shares were traded. CYTK stock price reached its highest trading level at $54.44 during the session, while it also had its lowest trading level at $51.17.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.19 and its Current Ratio is at 7.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 06 ’24 when FADY MALIK bought 7,300 shares for $53.71 per share.
Malik Fady Ibraham sold 7,300 shares of CYTK for $392,090 on Aug 06 ’24. The EVP Research & Development now owns 121,704 shares after completing the transaction at $53.71 per share. On Jul 30 ’24, another insider, ROBERT BLUM, who serves as the Officer of the company, bought 11,500 shares for $59.49 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6327936000 and an Enterprise Value of 5798068736. For the stock, the TTM Price-to-Sale (P/S) ratio is 1686.38. Its current Enterprise Value per Revenue stands at 1545.327 whereas that against EBITDA is -11.94.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98. The 50-Day Moving Average of the stock is -0.70%, while the 200-Day Moving Average is calculated to be -9.07%.
Shares Statistics:
For the past three months, CYTK has traded an average of 2.05M shares per day and 1317100 over the past ten days. A total of 117.11M shares are outstanding, with a floating share count of 113.26M. Insiders hold about 3.29% of the company’s shares, while institutions hold 98.59% stake in the company. Shares short for CYTK as of 1721001600 were 17464893 with a Short Ratio of 8.51, compared to 1718323200 on 16041724. Therefore, it implies a Short% of Shares Outstanding of 17464893 and a Short% of Float of 22.82.
